All In MedTech

FDA Clearance Tracker · P130013-S043

WATCHMAN™ and WATCHMAN FLX™ Left Atrial Appendage Closure Devices with Delivery Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 2, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 2, 2022

Approved

Time to decision

520 days

Received Mar 31, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P130013-S043
Device name
WATCHMAN™ and WATCHMAN FLX™ Left Atrial Appendage Closure Devices with Delivery Systems
Applicant location
Maple Grove, MN
Received
Mar 31, 2021
Decided
Sep 2, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130013

Device type

Device class
Class III

Every decision under product code NGV

FDA's approval statement

As written in FDA's record.

Approval for the addition of dual antiplatelet therapy (DAPT) as an alterative post-implant antithrombotic medication regimen.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.